Advanced Sulfation Biology Tools for Golgi-Resident Enzyme Drug Discovery and Selective Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TPST2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TPST2 Catalytic Domain (Luminal)-Fc HEK293 expressed, >95% purity, Endotoxin <1EU/ug. Sequence Verified. Contains the catalytic luminal domain with native Golgi glycosylation patterns. |
View TPST2 Products |
| Gene Delivery | TPST2 Lentivirus Premade Particles Full-length ORF for stable cell line construction. Preserves Type II membrane topology for native Golgi localization studies. |
View TPST2 Products |
| Detection & Benchmark | Anti-TPST2 Recombinant Monoclonal Antibody For Western Blot, ELISA, immunofluorescence, and as positive control for screening. |
View TPST2 Products |
| Validator | TPST2 siRNA Set Three validated siRNAs for knockdown verification and specificity controls in sulfation assays. |
View TPST2 Products |
| Paralog Control | TPST1 Catalytic Domain Paralog sulfotransferase for selectivity screening. Sequence Verified, >95% purity. |
View TPST1 Products |
| Related Target A | SLC35B2 (PAPS Transporter) Supplies substrate for sulfation; synergistic pathway target for combination studies. |
View SLC35B2 Products |
| Related Target B | CCR5 (Key Substrate) Evaluate downstream sulfation-dependent receptor function in inflammation or viral entry. |
View CCR5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & Native Golgi Topology | Soluble Luminal Domain expressed in HEK293 with native glycosylation for activity assays; Full-length Lentivirus for native Type II membrane topology preservation. |
| Paralog Selectivity (TPST1 vs. TPST2) | Matched pair of TPST1 and TPST2 catalytic domains (>95% purity) with identical tag configurations for direct comparative SPR/kinetic analysis. |
| Validated Controls & False Positive Mitigation | Clinical-grade Recombinant Benchmark Antibody and validated siRNA set for target knockdown and phenotypic rescue checks. Enzyme-dead mutant proteins also available. |
| Enzyme Conformation & Purity | Mammalian/insect expression ensures native-like folding; Theoretical MW verified by mass spec; Endotoxin <1EU/μg. |
Live TPST2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The recognition of protein tyrosine sulfation as a critical post-translational modification in immune regulation and coagulation is driving renewed interest in TPST2 as a druggable target. Historically considered challenging due to the highly conserved active site across the sulfotransferase family, recent advancements in structure-based drug design are shifting focus toward small-molecule allosteric inhibitors and targeted protein degraders (PROTACs). As first-generation tool compounds define the structure-activity relationship, the next wave of R&D is targeting paralog-selective TPST2 modulation to minimize off-target effects while preserving essential hemostatic functions. Cell-permeable chemical probes that can access the Golgi lumen catalytic site are also a key focus.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic consortia, Early biotech | Thrombosis, Inflammatory disease, HIV | Enzymatic Activity & Selectivity Assays (Need high-purity Luminal Domain and TPST1/TPST2 pair) |
| PROTAC / Targeted Degraders | Emerging Innovators | Cancer Metastasis, Immune modulation | Ternary Complex Validation (Need sequence-verified proteins with native folding) |
| Substrate-Competitive Peptides | Specialized peptide therapeutics firms | Immune modulation, Viral entry inhibition | SPR/Affinity Screening (Need TPST2 catalytic domain with correct folding) |
| Genetic Modulation (siRNA/ASO) | RNA-targeted platforms | Oncology (TME modulation), Target validation | Knockdown Validation (Need validated siRNA and overexpression lentivirus) |